


## TIMOR-LESTE

## EPIDEMIC ESTIMATES

|  | 2010                 | 2015                 | 2022                 |
|--|----------------------|----------------------|----------------------|
| <b>New HIV infections</b>                                      |                      |                      |                      |
| New HIV infections (all ages)                                  | <200<br>[<100– <200] | <200<br>[<100– <200] | <100<br>[<100– <200] |
| New HIV infections (0–14)                                      | ...<br>[...–...]     | ...<br>[...–...]     | ...<br>[...–...]     |
| New HIV infections (15–24)                                     | <100<br>[<100– <100] | <100<br>[<100– <100] | <100<br>[<100– <100] |
| New HIV infections (women, 15+)                                | <100<br>[<100– <100] | <100<br>[<100– <100] | <100<br>[<100– <100] |
| New HIV infections (men, 15+)                                  | <100<br>[<100– <100] | <100<br>[<100– <100] | <100<br>[<100– <100] |
| HIV incidence as new infections per 1000 uninfected population | 0.09 [0.07–0.12]     | 0.10 [0.08–0.12]     | 0.07 [0.04–0.11]     |
| <b>AIDS-related deaths</b>                                     |                      |                      |                      |
| AIDS-related deaths (all ages)                                 | <100<br>[<100– <100] | <100<br>[<100– <100] | <100<br>[<100– <100] |
| AIDS-related deaths (0–14)                                     | ...<br>[...–...]     | ...<br>[...–...]     | ...<br>[...–...]     |
| AIDS-related deaths (women, 15+)                               | <100<br>[<100– <100] | <100<br>[<100– <100] | <100<br>[<100– <100] |
| AIDS-related deaths (men, 15+)                                 | <100<br>[<100– <100] | <100<br>[<100– <100] | <100<br>[<100– <100] |
| <b>People living with HIV</b>                                  |                      |                      |                      |
| People living with HIV (all ages)                              | 790<br>[610–1000]    | 1100<br>[850–1300]   | 1500<br>[1100–1800]  |
| People living with HIV (0–14)                                  | ...<br>[...–...]     | ...<br>[...–...]     | ...<br>[...–...]     |
| People living with HIV (women, 15+)                            | <500<br>[<500– <500] | <500<br>[<500–560]   | 610<br>[<500–750]    |
| People living with HIV (men, 15+)                              | <500<br>[<500–520]   | 540<br>[<500–660]    | 780<br>[600–980]     |
| HIV prevalence (15–49)   | 0.1 [0.1–0.2]        | 0.1 [0.1–0.2]        | 0.2 [0.1–0.2]        |


## EPIDEMIC TRANSITION METRICS



## EXPENDITURES

|                             | Financing sources |                 |                       |                            |                           | Total          |
|-----------------------------|-------------------|-----------------|-----------------------|----------------------------|---------------------------|----------------|
|                             | Domestic private  | Domestic public | International: PEPFAR | International: Global Fund | International: all others |                |
| Last available report: 2022 | US\$ 0            | US\$ 41 200     | US\$ 0                | US\$ 1 182 889             | US\$ 0                    | US\$ 1 224 089 |

## HIV TESTING AND TREATMENT CASCADE



|                        | 80% [63–99%]<br>1168  | 69% [54–86%]<br>1009  | ...% [...–...%]<br>... |
|------------------------|-----------------------|-----------------------|------------------------|
| <b>All ages</b>        |                       |                       |                        |
| <b>Children (0–14)</b> | ...% [...–...%]<br>49 | ...% [...–...%]<br>35 | ...% [...–...%]<br>... |
| <b>Women (15+)</b>     | 63% [50–77%]<br>383   | 43% [35–53%]<br>264   | ...% [...–...%]<br>... |
| <b>Men (15+)</b>       | 94% [72–100%]<br>736  | 91% [70–100%]<br>710  | ...% [...–...%]<br>... |

## ELIMINATION OF VERTICAL TRANSMISSION

|   | 2015               | 2022               |
|---|--------------------|--------------------|
| Percentage of pregnant women living with HIV accessing antiretroviral medicines | ...%<br>[...–...%] | ...%<br>[...–...%] |
| Final vertical transmission rate including during breastfeeding                 | ...%<br>[...–...%] | ...%<br>[...–...%] |
| Early infant diagnosis  | ...%<br>[...–...%] | ...%<br>[...–...%] |